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Site-Selective cAMP Analogs at Micromolar Concentrations Induce Growth
Arrest and Differentiation of Acute Promyelocytic, Chronic Myelocytic, and
Acute Lymphocytic Human Leukemia Cell Lines
By Giampaolo Tortora, Pierosandro Tagliaferri, Timothy Clair, Oscar Colamonici,
Leonard M. Neckers, Roland K. Robins, and Yoon Sang Cho-Chung
Cyclic AMP (cAMP)-dependent protein kinase may play a
role in the functional and morphological differentiation of
leukemic cells. In this study, we showed that the cAMP
analogs. potent activators of protein kinase recently
shown to be selective for either site 1 or site 2 cAMP
binding sites of protein kinase, demonstrate potent growth
inhibition of acute promyelocytic, chronic myelocytic, and
acute lymphocytic leukemic cell lines with no sign of
toxicity. The growth inhibition accompanied monocytic
T HE CURRENT new approach to treating leukemia is to
promote cell differentiation rather than cell killing. In a
recent report,’ we demonstrated that site-selective cAMP
analogs, which are manyfold more active in protein kinase
activation than the previously studied cAMP analogs, exert a
major growth regulatory effect on a spectrum of human
cancer cell lines. By using experimental models of human
leukemic cell lines, we investigated whether the growth
regulatory effect of site-selective cAMP analogs accompa-
nies cell differentiation.
cAMP in mammalian cells functions through binding to
its receptor protein, cAMP-dependent protein kinase.2’3 Two
distinct isozymes, type I and type II protein kinases, have
been identified,4’5 and differential expression of these iso-
zymes has been linked to regulation of cell growth and
differentiation.’9 The regulatory subunits (R’, R”) of type I
and type II isozymes contain two types of binding sites for
cAMP, site I and site 2,b0hl and cAMP analogs that selec-
tively bind to either one of the two sites are known as site 1
selective and site 2 selective, respectively.” Generally, ana-
logs modified at the C-8 position are site 1 selective and those
modified at the C-6 position are site 2 selective.
Furthermore, these site-selective analogs in appropriate
combinations demonstrate synergism of binding and specific-
ity toward either type I or type II kinases.’”3 This unique
binding specificity of cAMP analogs that demonstrate site
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differentiation in HL-60 cells and a loss of nuclear terminal
deoxynucleotidyl transferase activity in MoIt-4 leukemic
cells. The growth inhibition also paralleled a decrease in
c-myc protein and R’ cAMP receptor protein. Thus, cAMP
analogs selective for either site 1 or site 2 of the protein
kinase appear to restore a coupling of proliferation and
maturation in leukemic cells.
This a US government work. There are no restrictions
on its use.
selectivity is not mimicked by cAMP itself or by previously
studied analogs.
In this study, we correlated the effect of site-selective
cAMP analogs on the growth and differentiation of leukemic
cells to the response of type I and type II protein kinases
present in the leukemic cells.
MATERIALS AND METHODS
cAMP, Ne,Ordibutyryl cAMP (DBcAMP) and 8-Br-cAMP
were from Boehringer Mannheim Biochemicals (Indianapolis). All
other cAMP analogs were synthesized” at the Nucleic Acid
Research Institute (Costa Mesa, CA). The leukemic cell lines used
include HL-60 (acute promyelocytic), K-562 (chronic myelocytic),
myc-K562 (chronic myelocytic), and Molt-4 (acute T lymphocytic).
All leukemic cell lines except myc-K562 were obtained from Amen-
can Type Culture Collection (Rockville, MD), and the myc-K562
cell line was produced by infecting K-562 with a retroviral vector
supplied by L. Wolff (National Cancer Institute, NIH, Bethesda,
MD).
Cells were grown in suspension culture in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS), penicillin (50
U/mL), streptomycin (500 g/mL), 10 mmol/L HEPES buffer,
and extra glutamine. For cell growth experiments, cells were treated
with cAMP analogs one time at 3 hours after seeding, and cell counts
in duplicate were performed on a Coulter counter 48 and 72 hours
later. Surface antigen analysis of HL-60 cells was performed by flow
cytometry using a panel of monoclonal antibodies reactive with
either myeloid cells or monocytic cells. Terminal deoxynucleotidyl
transferase (TdT)s was assayed by an immunoperoxidase method
using the Bethesda Research Laboratory’s (Gaithersburg, MD) TdT
fluorescence kit. Western blotting of c-myc protein was performed
by the method previously described”7 using c-myc antibody
15206D1 I (Scripps Clinic and Research Foundation, La Jolla, CA).
Photoaffinity labeling of cAMP receptor proteins with 8-N3-
[32PJcAMP (ICN Pharmaceuticals, Irvine, CA) was performed as
previously 
RESULTS
A variety of cAMP analogs, modified at either the C-6 or
C-8 positions of the adenine moiety at various concentra-
tions, were tested for their growth inhibitory effect on
leukemic cell lines (Table 1 ). Among the C-8 analogs (site 1
selective) tested, 8-Cl-cAMP exhibited the most potency,
demonstrating 50% growth inhibition at 5-20 tmol/L con-
centrations (ICse) in all four leukemic cell lines. 8-Br-,
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Table 1 . Effect of Site-Selective cAMP Analogs on Growth of
Leukemic Cell Lines
NUCIeOtide
Analog CAMP Analog
Inhib ition of Gr owth IC,,, (zmo1/L)
HL-60 Molt-4 K-562 myc-K562
C-8 8-Chloro
8-Bromo
8-Thiomethyl
8-Aminomethyl
10
50
1 00
1 00
5
100
100
100
20
100
1 00
1 00
20
100
100
100
C-6 N6-Benzyl
N-Benzoyl
Ne. O2-Dibutyryl
20
50
500
10
40
- ‘
27
45
1 .000
30
50
1,000
No grows h inhibition.
8-thiomethyl-, and 8-aminomethyl-cAMP were 5 to 20 times
less potent than 8-Cl-cAMP. N6-benzyl-cAMP was the most
potent of the C-6 analogs (site 2 selective) tested with IC50
values of 10 to 30 tmol/L. N6-benzoyl-cAMP, which has
structural similarity with N6-benzyl-cAMP, exhibited IC
values of 40 to 50 tmol/L (Table 1 ). DBcAMP, the analog
most commonly used in the past studies,’92’ exhibited the
least potency, with IC values of 500 to 1,000 jsmol/L, and
in Molt-4, the 50% growth inhibition (IC) could not be
obtained (Table 1 ). Growth inhibition by the site-selective
cAMP analogs was not due to cell killing; the cells were 80%
to 90% viable as determined by exclusion of trypan blue
dye.
Phosphodiesterase inhibitors, such as theophylline (0.1
mmol/L) or 1 -methyl-3-isobutylxanthine (0.5 mmol/L),
each alone had little or no growth inhibitory effect, and the
inhibitors could not enhance the analog effect when added in
combination with the analog (data not shown). These results
suggest that the analogs produced growth inhibition at
concentrations below which the degradation by phosphodies-
terase could take place and also that the growth inhibition
was not due to raising cellular cAMP. Our results are
compatible with recent reports that in intact rat hepato-
cytes22 and rat heart and rat fat cells23 site-selective cAMP
analogs caused a decrease rather than an increase in cellular
cAMP.
We examined the effect ofsite-selective cAMP analogs on
the expression of differentiation markers in HL-60 cells to
determine if the growth-arrested HL-60 cells are more
differentiated than the untreated cells. Treatment for 3 days
with 8-Cl-cAMP exhibiting 90% cell viability induced a
marked increase in the expression of monocyte-specific sur-
face antigens (MO2, 0KM5) and a decrease in markers
related to the immature progenitor cells (My7, My9) (Table
2).2425 The 8-Cl-cAMP-treated cells became strongly posi-
tive for a-naphthyl butyrate esterase, a cytochemical marker
for monocytes, and underwent a monocytic morphological
transformation characterized by a decreased nuclear-to-
cytoplasm ratio, abundant ruffled and vacuolated cytoplasm,
and loss of nucleoli (data not shown).
Disappearance of cellular TdT has been considered as a
differentiation marker for human T lymphocytic leukemia.’5
Treatment of Molt-4 (acute T lymphocytic) leukemia cells
with 8-Cl-cAMP (10 Mmol/L) caused a time-dependent
decrease in TdT activity; at 2 days after the treatment, TdT
Table 2. Modulation of Differentiation Markers
in HL-60 Cells by 8-Cl-cAMP
Markers
Control
(%)
8-CI-CAMP
(20tmol/L)
Positive
My7
My9
LeuMl
LeuM5
MO2
0KM5
81
75
72
0
0
0
11
54
0
0
75
51
‘Seventy percent gro wth inhibition wit h 90% cell viability.
activity decreased to 50% of that in untreated control cells,
and by day 4, the activity decreased to 10% of the untreated
control levels. Moreover, treatment for 4 days with 8-
Cl-cAMP in combination with N6-benzyl cAMP (20 Mmol/
L) caused almost complete loss (>95%) ofTdT activity (data
not shown). These cells exhibiting the loss of TdT demon-
strated >90% viability.
By using a propidium iodide staining method, we exam-
med whether the reduced cell proliferation observed in the
leukemic cell lines after treatment with the analogs was due
to a specific block in one phase of the cell cycle.26’27 The
results showed that the fractions of cells in each phase of cell
cycle were not appreciably different between the control cells
and the cells treated with the analogs (data not shown).
The type I isozyme ofcAMP-dependent protein kinase has
been considered to be involved in cell proliferation and
transformation, whereas the type II isozyme is involved in
cell differentiation and inhibition of cell growth.9 Because
type I and type II protein kinase differ only in their regula-
tory subunits (the cAMP binding receptor protein),4’5 we
measured, using the photoaffinity ligand 8-N3-[32P]cAMP,’8
the cAMP receptor protein during the analog treatment of
these leukemic cells. As shown in Fig IA, the untreated
Molt-4 leukemic cells contained a major cAMP receptor
protein with a mol wt of 48,000 (lane 1), the R’ cAMP
receptor protein (the regulatory subunit of type I protein
kinase).2 When the cells were treated for 3 days with
8-Cl-cAMP (lane 2), the R’ receptor protein markedly
decreased, whereas the R’ protein remained without appre-
ciable change when the cells were treated with DBcAMP
(lane 3). That the decrease of the R’ receptor photoaffinity
labeling found after 8-Cl-cAMP treatment could be due to
the presence of bound 8-Cl-cAMP to the R’ receptor is
unlikely; 8-Cl-cAMP, like 8-piperidino-cAMP,’3 selectively
binds to site I of R” but binds to site 2 of R’ receptor (D.
#{216}greid, confidential personal communication); thus, 8-Cl-
cAMP bound to site 2 of R’ would synergistically enhance,
instead of interfering with, the site I-selective binding of
8-N3-[32P]cAMP.
8-Cl-cAMP also caused a marked reduction of c-myc
protein level (Fig 1B, lane 2), whereas DBcAMP (lane 3) did
not affect the c-myc protein level . 8-CI-adenosine (5 zmol/
L), despite its strong growth inhibitory effect (85%), affected
neither the R’ level nor the c-myc protein level (Table of Fig
1), indicating that a decrease in R’ and c-myc protein levels
caused by 8-Cl-cAMP treatment does not merely reflect
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myc
PROT
-.-c-myc
PROT.
LANE
RELATIVE LEVEL
%GROWTHcAMP
RECEPTOR
(R’)
c-myc
PROTEIN
1, CONTROL 1.0 ±o.io 1.O±o.ii 100
2, 8-Cl (5)tM) 0.02±0.005 N.D. 40
3, DIBUTYRYL
(1mM)
1.1 ±0.12 1.1±0.12 80
4, 8-CI-ADENOSINE
(5jtM) i .o ± o.ii i .o± o.ii 35
Fig 1 . Effect of site-selective cAMP analog treatment on the
levels of cAMP receptor protein and c-myc protein. (A) Photoacti-
vated incorporation of 8-N3-[P]cAMP; (B) Western blotting of
c-myc protein. R’. the 48,000 mol wt R’ cAMP receptor protein2; R”,
the 56.000 mol wt Ru cAMP receptor protein; c-myc protein. a
purified preparation of c-myc protein.’ Lane 1 ,untreated control
cells; lanes 2 through 4. the cells treated for 3 days with 8-
Cl-cAMP (5 imol/L), DBcAMP (1 mmol/L), and 8-CI-adenosine (5
Mmol/L), respectively. M, marker proteins of known mol wt
(Bethesda Research Laboratories). Each lane contained 100 .tg
protein for sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE). The cell pellets, after two washes with phos-
phate-buffered saline. were suspended in buffer ten (0.1 mol/L
NaCI, 5 mmol/L MgCI2. 1 % Nonidet P-40. 0.5% Na deoxycholate, 2
KIU/mL bovine aprotinin. 20 mmol/L Tris-HCI. pH 7.4) (2 x iO
cells/mL). vortexed, passed through a 22-gauge needle ten times.
allowed to stand for 30 minutes at 4’C, and centrifuged at 750 g for
20 minutes at 4’C; the resulting supernatants were used as cell
lysates. Numbers in panel represent the average value ± SE of
seven separate experiments. ND. nondetectable.
growth inhibition or cell death in general. A similar decrease
in R’ and c-myc protein levels also occurred in other leukemic
lines, K-562, myc-K562, and l-IL-60, after 8-Cl-cAMP
treatment. The R” cAMP receptor protein was not detected
in Molt-4 but was measurable in other leukemic cell lines.
The analog treatment did not affect the R” levels in these
leukemic cells.
DISCUSSION
To our knowledge, the present data represent the first
unequivocal demonstration that site-selective cAMP analogs
are capable of exerting a major effect on the growth of
promyelocytic, chronic myelocytic, and acute T lymphocytic
human leukemic cell lines at micromolar concentrations. All
previously reported studies of cAMP regulation of cell
growth, using DBcAMP, reported effective concentrations in
an unphysiologic millimolar range.’92’ The analog effect was
not due to raising of cellular cAMP level as was previously
believed, because phosphodiesterase inhibitors i n combina-
tion with the analog did not enhance the analog effect. The
analogs worked directly through cAMP receptor protein, the
regulatory subunit of cAMP-dependent protein kinase.4’5
Among the site-selective analogs tested, 8-Cl-cAMP, which
has a strong site 1 selectivity for type II protein kinase
(90-fold more than that of cAMP, D. #{216}greid, confidential
personal communication), exhibited the most potency. The
analog effect correlated with a selective modulation of two
types ofcAMP receptor proteins-a marked reduction in the
R’ receptor, which was previously related to cell growth and
transformation,78 with no change in the R” receptor, which
was related to growth arrest and differentiation.6’9
This selective modulation ofthe R’ and R” cAMP receptor
protein was not achieved by the early-known analog,
DBcAMP. The growth inhibition also caused a marked
reduction in c-myc protein level. The decrease in the R’
cAMP receptor and c-myc protein was not observed when
cells were growth arrested by 8-CI-adenosine, indicating that
the analog effect was not due to its adenosine metabolite.
The growth arrest by the analogs accompanied differen-
tiation of the leukemic cells, as shown by the expression of
several surface antigens specific for monocytic differentia-
tion in HL-60 cells and a loss ofthe activity ofTdT, a marker
enzyme for cell immaturity in Molt-4 cells. Despite the
appearance of markers of mature phenotype and definitive
growth arrest shown in the analog-treated cells, the cell cycle
phase distribution between the treated and untreated cells
was similar; namely, the treated cells exhibited no
arrest.
In normal myeloid cell precursors, the growth inducers
induce cell viability and cell multiplication and also produc-
tion of differentiation inducers.3#{176}33 In leukemic cells, there-
fore, continuous production of growth inducers may be
essential for continuous production of differentiation induc-
ers to achieve their terminal differentiation. The site-
selective cAMP analogs, which produce growth arrest while
allowing the cells to progress through their normal cell cycle
but at a slower rate, may be ideal agents for terminal
differentiation of leukemic cells because they would allow
continuous production of differentiation inducers. Thus, site-
selective cAMP analogs appear to restore the balance
between proliferation and maturation of leukemic cells.
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